Mantle Cell Lymphoma

>

CURE’s mantle cell lymphoma (MCL) page features the latest cancer news and updates on mantle cell lymphoma Through articles, videos, podcasts, and more, CURE brings readers the insights of experts, cancer survivors, patients, and advocates to ensure everyone is up to date in mantle cell lymphoma.

Latest News

image of mantle cell lymphoma
Lunsumio plus Polivy Associated With Responses in MCL

September 9th 2025

For patients with relapsed/refractory mantle cell lymphoma Lunsumio plus Polivy was associated with durable responses.

Dr. Tycel Phillips discusses the FDA approval of Calquence plus bendamustine and Rituxan in untreated MCL. | © Digilife - stock.adobe.com
FDA Approval of Calquence Combo Brings Optimism in MCL

February 11th 2025

Dr. Tycel Phillips discusses the FDA approval of a Calquence combo in MCL: © Zhanna - stock.adobe.com
FDA-Approved Calquence Combo Is First and Only of Its Kind in MCL

February 5th 2025

FDA Approved Image.
Breaking Down Cancer Therapies Approved by the FDA in January 2025

February 3rd 2025

Image of 'FDA Approval'
FDA Approves Calquence Combo for Mantle Cell Lymphoma

January 16th 2025

Managing Mantle Cell Lymphoma (MCL) after Relapsed on First Treatment

An interview with Dr. Luhua (Michael) Wang, MD, Department of Lymphoma and Myeloma, Division of Cancer Medicine, MD Anderson Cancer Center

Dr. Luhua (Michael) Wang
Video Series
Video Interviews

More News